Dr. René C.-Gaudreault, l. pharm., PhD, is a senior researcher at the Centre de recherche du CHU de Québec-Laval University. He is the director of a medicinal chemistry laboratory based at the Hôpital Saint-François d’Assise. In addition, he is a full professor in the Department of molecular medicine at the Laval University School of Medicine. Dr. C.-Gaudreault is the author and coauthor of over 100 publications in peer-reviewed journals, and the inventor and co-inventor of numerous patents. He is the recipient of several prizes and distinctions, notably the Frisen-Rygel Medal for an outstanding Canadian academic discovery leading to uniquely positioned commercialization opportunities. His research programs mainly focus on the design and development of new anti-inflammatory, antipsoriatic, and anticancer drugs for personalized therapies.

Development of new anticancer and anti-inflammatory drugs for personalized medicine

Cancer and inflammation-based diseases are major health concerns in Canada and worldwide. Despite important medical breakthroughs over the past 75 years, few treatments are efficient and devoid of deleterious effects. Consequently, new drugs and treatments are required to improve both the quality of life and the life expectancy of patients. It is in this context that Dr. Gaudreault’s laboratory is involved in the drug design and development of new anticancer agents and their prodrugs, and non-steroidal anti-inflammatory agents exhibiting suitable biopharmaceutical and pharmacodynamic properties for preclinical and clinical studies. In addition, Dr. Gaudreault’s team is involved in the determination of their mechanisms of action and their potential therapeutical applications, using various cellular and molecular pharmacology approaches to support the design and the optimization of the next generations of molecules. Dr. Gaudreault’s research programs involve several interrelated and complementary disciplines, including molecular design and modelling, medicinal chemistry, cell biology, molecular pharmacology, and animal experimentation. The outcomes of these projects will contribute to new and efficient drugs for applications in personalized medicine.

Hôpital Saint-François d'Assise
10, rue de l'Espinay
E0-171
Québec, Québec
Canada G1L 3L5
55 entries « 5 of 6 »

Fortin S, Moreau E, Lacroix J, Teulade JC, Patenaude A, C-Gaudreault R

N-Phenyl-N'-(2-chloroethyl)urea analogues of combretastatin A-4: Is the N-phenyl-N'-(2-chloroethyl)urea pharmacophore mimicking the trimethoxy phenyl moiety?

Journal Article

Bioorg Med Chem Lett, 17 (7), pp. 2000-4, 2007, ISSN: 0960-894X.

Abstract | Links:

Patenaude A, Deschesnes RG, Rousseau JL, Petitclerc E, Lacroix J, Cote MF, C-Gaudreault R

New soft alkylating agents with enhanced cytotoxicity against cancer cells resistant to chemotherapeutics and hypoxia.

Journal Article

Cancer Res, 67 (5), pp. 2306-16, 2007, ISSN: 0008-5472.

Abstract | Links:

Deschesnes RG, Patenaude A, Rousseau JL, Fortin JS, Ricard C, Cote MF, Huot J, C-Gaudreault R, Petitclerc E

Microtubule-destabilizing agents induce focal adhesion structure disorganization and anoikis in cancer cells.

Journal Article

J Pharmacol Exp Ther, 320 (2), pp. 853-64, 2007, ISSN: 0022-3565.

Abstract | Links:

Fortin S, Moreau E, Patenaude A, Desjardins M, Lacroix J, Rousseau JL, C-Gaudreault R

N-Phenyl-N'-(2-chloroethyl)ureas (CEU) as potential antineoplastic agents. Part 2: role of omega-hydroxyl group in the covalent binding to beta-tubulin.

Journal Article

Bioorg Med Chem, 15 (3), pp. 1430-8, 2007, ISSN: 0968-0896.

Abstract | Links:

Rabouin D, Perron V, N'Zemba B, Gupta A, C-Gaudreault R, Bérubé G

Synthesis and preliminary biological evaluation of estrone dimers

Journal Article

Lett Drug Des Discov, 4 (3), pp. 171-174, 2007, ISSN: 1570-1808.

Labrie P, Maddaford SP, Fortin S, Rakhit S, Kotra LP, Gaudreault RC

A comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) of anthranilamide derivatives that are multidrug resistance modulators.

Journal Article

J Med Chem, 49 (26), pp. 7646-60, 2006, ISSN: 0022-2623.

Abstract | Links:

Labrie P, Maddaford SP, Lacroix J, Catalano C, Lee DK, Rakhit S, Gaudreault RC

In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity at CYP-450.

Journal Article

Bioorg Med Chem, 14 (23), pp. 7972-87, 2006, ISSN: 0968-0896.

Abstract | Links:

Berube G, Rabouin D, Perron V, N'Zemba B, Gaudreault RC, Parent S, Asselin E

Synthesis of unique 17beta-estradiol homo-dimers, estrogen receptors binding affinity evaluation and cytocidal activity on breast, intestinal and skin cancer cell lines.

Journal Article

Steroids, 71 (10), pp. 911-21, 2006, ISSN: 0039-128X.

Abstract | Links:

Moreau E, Fortin S, Desjardins M, Rousseau JL, Petitclerc E, C-Gaudreault R

Optimized N-phenyl-N'-(2-chloroethyl)ureas as potential antineoplastic agents: synthesis and growth inhibition activity.

Journal Article

Bioorg Med Chem, 13 (24), pp. 6703-12, 2005, ISSN: 0968-0896.

Abstract | Links:

Morissette G, Moreau E, C-Gaudreault R, Marceau F

N-substituted 4-aminobenzamides (procainamide analogs): an assessment of multiple cellular effects concerning ion trapping.

Journal Article

Mol Pharmacol, 68 (6), pp. 1576-89, 2005, ISSN: 0026-895X.

Abstract | Links:

55 entries « 5 of 6 »
Signaler des ajouts ou des modifications

Active projects

  • Accélérer et rendre plus accessibles les tests précliniques en chimiothérapie et la radiothérapie du cancer, en utilisant le modèle de l'oeuf et des stratégies d'impression 3D, Subvention, Fonds de recherche du Québec - Nature et technologies, Projet de recherche en équipe, from 2020-04-01 to 2023-03-31
  • Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • Centre de recherche sur le cancer, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-05-01 to 2022-06-13
  • Validation of Highly Potent Substituted Phenyl Alkylureas as Antipsoriatic Agents, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2018-04-01 to 2021-03-31

Recently finished projects

  • Comprendre le rôle des cellules immunitaires dans le psoriasis grâce au génie tissulaire, Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2014-04-01 to 2020-03-31
  • Les phénylimidazolidones, de nouvelles molécules pour le traitement personnalisé des cancers du sein hormono- et chimiorésistants: du laboratoire vers la clinique., Subvention, Fondation de l'Université Laval, from 2015-10-01 to 2019-07-30
  • Substituted phenyl alkylureas as new potent antipsoriatic drugs: Mechanism of action and structure-activity relationships., Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2015-07-01 to 2020-06-30
Data provided by the Université Laval research projects registery